• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Real-world experience of bimekizumab for adult patients with plaque psoriasis: A 16-week multicenter retrospective study.

作者信息

Rimke Alexander, Sood Siddhartha, Rankin Brian D, Abduelmula Abrahim, Georgakopoulos Jorge R, Maliyar Khalad, Bagit Ahmed, Leung Fernejoy, Stark Lauren A, Vender Ronald, Yeung Jensen, Prajapati Vimal H

机构信息

Dermatology Research Institute, Calgary, Alberta, Canada.

Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.

出版信息

J Am Acad Dermatol. 2024 Aug;91(2):359-361. doi: 10.1016/j.jaad.2024.04.027. Epub 2024 Apr 20.

DOI:10.1016/j.jaad.2024.04.027
PMID:38649098
Abstract
摘要

相似文献

1
Real-world experience of bimekizumab for adult patients with plaque psoriasis: A 16-week multicenter retrospective study.成人斑块状银屑病患者使用比美吉珠单抗的真实世界经验：一项为期16周的多中心回顾性研究。
J Am Acad Dermatol. 2024 Aug;91(2):359-361. doi: 10.1016/j.jaad.2024.04.027. Epub 2024 Apr 20.
2
Efficacy and Safety of bimekizumab in elderly patients: real-world multicenter retrospective study - IL PSO (Italian Landscape Psoriasis).比美吉珠单抗治疗老年患者的疗效和安全性：真实世界多中心回顾性研究-IL PSO（意大利银屑病景观）。
J Dermatolog Treat. 2024 Dec;35(1):2393376. doi: 10.1080/09546634.2024.2393376. Epub 2024 Aug 20.
3
Bimekizumab in psoriasis: a monocentric study evaluating short- and mid-term effectiveness and safety profile in a real-world setting.比美吉珠单抗治疗银屑病：一项真实世界环境下评估短期和中期疗效及安全性的单中心研究。
Arch Dermatol Res. 2024 Apr 25;316(5):133. doi: 10.1007/s00403-024-02868-7.
4
Bimekizumab for patients with moderate to severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled, phase 2b extension study.比美克珠单抗治疗中重度斑块型银屑病患者：来自 BE ABLE 2 的 60 周结果，一项随机、双盲、安慰剂对照的 2b 期扩展研究。
J Am Acad Dermatol. 2020 Nov;83(5):1367-1374. doi: 10.1016/j.jaad.2020.05.105. Epub 2020 May 29.
5
Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial.比美吉珠单抗治疗中重度斑块型银屑病的疗效和安全性（BE READY）：一项多中心、双盲、安慰剂对照、随机撤药阶段 3 期临床试验。
Lancet. 2021 Feb 6;397(10273):475-486. doi: 10.1016/S0140-6736(21)00126-4.
6
Bimekizumab versus Adalimumab in Plaque Psoriasis.比美吉单抗与阿达木单抗治疗斑块状银屑病的疗效比较。
N Engl J Med. 2021 Jul 8;385(2):130-141. doi: 10.1056/NEJMoa2102388. Epub 2021 Apr 23.
7
Bimekizumab versus Secukinumab in Plaque Psoriasis.比美吉珠单抗与司库奇尤单抗治疗斑块状银屑病的疗效比较。
N Engl J Med. 2021 Jul 8;385(2):142-152. doi: 10.1056/NEJMoa2102383. Epub 2021 Apr 23.
8
Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial.倍美克单抗治疗银屑病患者的白介素 17A 和白介素 17F 的双重中和作用：来自 BE ABLE 1 的 12 周随机、双盲、安慰剂对照 2b 期试验结果。
J Am Acad Dermatol. 2018 Aug;79(2):277-286.e10. doi: 10.1016/j.jaad.2018.03.037. Epub 2018 Mar 30.
9
Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial.比美吉珠单抗与乌司奴单抗治疗中度至重度斑块型银屑病（BE VIVID）：一项为期 52 周、多中心、双盲、活性对照和安慰剂对照的 3 期临床试验的疗效和安全性。
Lancet. 2021 Feb 6;397(10273):487-498. doi: 10.1016/S0140-6736(21)00125-2.
10
Mental health outcomes in patients with moderate to severe psoriasis treated with bimekizumab: Analysis of phase 2/3 randomized trials.中重度斑块状银屑病患者接受比美吉珠单抗治疗的心理健康结局： 2/3 期随机试验分析。
J Am Acad Dermatol. 2024 Jul;91(1):72-81. doi: 10.1016/j.jaad.2024.02.039. Epub 2024 Mar 4.

引用本文的文献

1
Real-World Experience of Bimekizumab in a Cohort of 109 Patients Over 48 Weeks and Identification of Predictive Factors for an Early Super Response and Risk of Adverse Events.109例患者使用比美吉珠单抗48周的真实世界经验以及早期超反应预测因素和不良事件风险的识别。
Psoriasis (Auckl). 2025 Apr 11;15:145-158. doi: 10.2147/PTT.S514249. eCollection 2025.
2
Real-World Experience of Bimekizumab for Plaque Psoriasis in Adult Patients with Prior Exposure to Interleukin-23 Inhibitors: A Multicenter Retrospective Study.成人患者中先前使用过白细胞介素-23抑制剂的斑块状银屑病患者使用比美吉珠单抗的真实世界经验：一项多中心回顾性研究
Am J Clin Dermatol. 2025 Mar;26(2):301-304. doi: 10.1007/s40257-025-00922-2. Epub 2025 Feb 3.
3
Long-term efficacy and safety of bimekizumab in real-world setting: a 52-week prospective study.
现实环境中比美吉珠单抗的长期疗效和安全性：一项为期52周的前瞻性研究。
Arch Dermatol Res. 2024 Dec 12;317(1):102. doi: 10.1007/s00403-024-03594-w.
4
Real-World Experience of Bimekizumab in an Elderly Patients Cohort with Plaque-Type Psoriasis: A 24-Week Retrospective Study.比美吉珠单抗在老年斑块型银屑病患者队列中的真实世界经验：一项24周的回顾性研究。
Clin Cosmet Investig Dermatol. 2024 Sep 30;17:2177-2181. doi: 10.2147/CCID.S487869. eCollection 2024.